Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidemic and hyperlipidemic individuals

Thrombosis and Haemostasis

Volumn 80, Issue 6, 1998, Pages 903-908

  Weng, Xiaoduan ^a   Roederer, Ghislaine O ^a   Beaulieu, Raymond ^b   Cloutier, Guy ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; CHOLESTEROL; FIBRINOGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OROSOMUCOID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REFLECTOMETRY;

EID: 0031792541     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615386     Document Type: Article

References (52)

1. Vayá A, Martínez M, Carmena R, Aznar J. Red blood cell aggregation and primary hyperlipoproteinemia. Thrombosis Research 1993; 72: 119-26.
2. Razavian SM, Atger V, Giral PH, Cambillau M, Del-Pino M, Simon AC, Moatti N, Levenson J. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arteriosclerosis & Thrombosis 1994; 14: 361-6.
3. Caimi G, Presti RL, Canino B, Montana M, Francavilla G, Grifo G, Romano A, Catania A, Sarno A, Vittorio C. Hemorheologic profile of hyperlipidemic patients treated with Gemfibrozil. Curr Therapeutic Res 1996; 57: 327-35.
4. Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J. Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modification in familial hypercholesterolemia treated with lovastatin. Thrombosis Research 1996; 83: 375-88.
5. Ruhenstroth-Bauer G, Mössmer G, Ottl J, Koenig-Erich S, Heinemann G. Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. Eur J Clin Invest 1987; 17: 275-9.
6. Neumann FJ, Tillmanns H, Roebruck P, Zimmermann R, Haupt HM, Kübler W. Haemorrheological abnormalities in unstable angina pectoris: A relation independent of risk factor profile and angiographic severity. Br Heart J 1989; 62: 421-8.
7. Hahn R, Müller-Seydlitz PM, Jöckel KH, Hubert H, Heimburg P. Viscoelasticity and red blood cell aggregation in patients with coronary heart disease. Angiology 1989; 40: 914-20.
8. Neumann FJ, Katus HA, Hoberg E, Roebruck P, Braun M, Haupt HM, Tillmanns H, Kübler W: Increased plasma viscosity and erythrocyte aggregation: Indicators of an unfavourable clinical outcome in patients with unstable angina pectoris. Br Heart J 1991; 66: 425-30.
9. Demiroglu H, Barista I, Dündar S. Erythrocyte aggregability in patients with coronary heart disease. Clinical Hemorheology 1996; 16: 313-7.
10. Tanahashi N, Gotoh F, Tomita M, Shinohara T, Terayama Y, Mihara B, Ohta K, Nara M. Enhanced erythrocyte aggregability in occlusive cerebrovascular disease. Stroke 1989; 20: 1202-7.
11. Tanahashi N, Fukuuchi Y, Tomita M, Matsuoka S, Takeda H. Erythrocyte aggregability in patients with cerebral infarction with special reference to diabetes mellitus. Clinical Hemorheology 1993; 13: 253-9.
12. Mchedlishvili G, Shakarishvili R, Aloeva M, Momtselidze N. Elaborated -"Georgian index" of erythrocyte aggregability characterizing the microrheological disorders associated with brain infarct. Clinical Hemorheology 1995; 15: 783-93.
13. Tanahashi N, Tomita M, Kobari M, Takeda H, Yokoyama M, Takao M, Fukuuchi Y. Platelet activation and erythrocyte aggregation rate in patients with cerebral infarction. Clinical Hemorheology 1996; 16: 497-505.
14. Tanahashi N, Tomita M, Kobari M, Takeda H, Yokoyama M, Fukuuchi Y. Aspirin improves the enhanced erythrocyte aggregability in patients with cerebral infarction. J Neurological Sciences 1996; 139: 137-40.
15. Faber CG, Troost J, Vermes I, Lodder J, Kalsbeek-Batenburg EM, Kessels F, Haanen C. Enhanced red blood cell aggregation unrelated to fibrinogen: A possible stroke mechanism in young patients. Cerebrovasc Dis 1997; 7: 70-6.
16. Hayakawa M, Kuzuya F. Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders. Angiology 1991; 42: 747-53.
17. Chabanel A, Horellou MH, Conard J, Samama MM. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment. Br J Haematology 1994; 88: 174-9.
18. Zuccarelli F, Taccoen A, Razavian M, Chabanel A. Increasing erythrocyte aggregability with the progressive grades of chronic venous insufficiency: importance and mechanisms. J Cardiovasc Surg 1995; 36: 387-91.
19. Chien S. Blood rheology and its relation to flow resistance and transcapillary exchange, with special reference to shock. Adv Microcirc 1969; 2: 89-103.
20. Schmid-Schönbein H, Gallasch G, Volger E, Klose HJ. Microrheology and protein chemistry of pathological red cell aggregation (blood sludge) studied in vitro. Biorheology 1973; 10: 213-27.
21. Schmid-Schönbein H. Critical closing pressure or yield shear stress as the cause of disturbed peripheral circulation? Acta Chir Scand 1976; 10-9.
22. Lipowsky HH, Kovalcheck S, Zweifach BW. The distribution of blood Theological parameters in the microvasculature of cat mesentery. Circ Res 1978; 43: 738-49.
23. Dupuy-Fons C, Brun JF, Pellerin F, Laborde JC, Bardet L, Orsetti A, Janbon C. Relationships between blood rheology and transcutaneous oxygen pressure in peripheral occlusive arterial disease. Clinical Hemorheology 1995; 15: 191-9.
24. Demiroglu H. The importance of erythrocyte aggregation in blood rheology: Considerations on the pathophysiology of thrombotic disorders. Blood 1997; 89: 4236.
25. Verstraete M, V Fuster, EJ Topol. Cardiovascular thrombosis. Thrombocardiology and thromboneurology. Philadelphia, New York, Lippincott: Raven,1998; pp 1-849.
26. Imaizumi K, Shiga T. Effect of immunoglobulins and IgG-fragments on the human erythrocyte aggregation, studied by a rheoscope combined with image analyzer. Biorheology 1983; 20: 569-77.
27. Rampling MW, Whittingstall P, Linderkamp O. The effects of fibrinogen and its plasmin degradation products on the rheology of erythrocyte suspensions. Clinical Hemorheology 1984; 4: 533-43.
28. Lowe GDO. Topics in preventive cardiology. The impact of fibrinogen on arterial disease. The Netherlands: Excerpta Medica 1993; pp 3-32.
29. Maeda N, Shiga T. Opposite effect of albumin on the erythrocyte aggregation induced by immunoglobulin G and fibrinogen. Biochimica & Biophysica Acta 1986; 855: 127-35.
30. Weng X, Cloutier G, Beaulieu R, Roederer GO. Influence of acute-phase proteins on erythrocyte aggregation. Am J Physiol 1996; 271: H2346-H52.
31. Poggi M, Palareti G, Biagi R, Legnani C, Parenti M, Babini AC, Baraldi L, Coccheri S. Prolonged very low calorie diet in highly obese subjects reduces plasma viscosity and red cell aggregation but not fibrinogen. Int J Obesity 1994; 18: 490-6.
32. Rothwell M, Rampling MW, Cholerton S, Sever PS. Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers. Br J Haematology 1991; 79: 500-3.
33. Pignon B, Jolly D, Potron G, Lartigue B, Vilque JP, Nguyen P, Etienne JC, Stoltz JF. Erythrocyte aggregation - Determination of normal values: Influence of age, sex, hormonal state, oestroprogestative treatment, haematological parameters and cigarette smoking. Nouv Rev Fr Hematol 1994; 36: 431-9.
34. Petralito A. Erythrocyte aggregation in different stages of arterial hypertension. Thrombosis & Haemostasis 1985; 54: 555.
35. Donner M, Siadat M, Stoltz JF. Erythrocyte aggregation: Approach by light scattering determination. Biorheology 1988; 25: 367-75.
36. Pignon B, Muller S, Jolly D, Siadat M, Petitfrere E, Vessel B, Donner M, Potron G, Stoltz JF. Validation d'une méthode d'approche de l'agrégation érythrocytaire par retrodiffusion laser. Hémorhéologie et agrégation érythrocytaire. In Stoltz JF (ed). Éditions Médicales Internationales 1988; pp 65-74.
37. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
38. Chien S. Biophysical behavior of red cells in suspensions. In: The red blood cell. Surgenor DM (ed). New York, San Francisco, London: Academic Press 1975; pp 1031-133.
39. Seaman GVF. Electrokinetic behavior of red cells. In: The red blood cell. Surgenor DM (ed). San Francisco, London: Academic Press 1975; pp 1135 to 223.
40. Maeda N, Seike M, Suzuki Y, Shiga T. Effect of pH on the velocity of erythrocyte aggregation. Biorheology 1988; 25: 25-30.
41. Maeda N. Erythrocyte rheology in microcirculation. Jpn J Physiol 1996; 46: 1-14.
42. Lowe GDO. Agents lowering blood viscosity, including defibrinogenating agents. In: Cardiovascular thrombosis: Thrombocardiology and thromboneurology. Verstraete M, Fuster V, Topol EJ (eds). Philadelphia, New York, Lippincott: Raven 1998; pp 321-33.
43. Chesebro JH, Fuster V. Valvular heart disease and prosthetic heart valves. In: Cardiovascular thrombosis: Thrombocardiology and thrombon urology. Verstraete M, Fuster V, Topol EJ (eds). Philadelphia, New York, Lippincott : Raven 1998; pp 365-94.
44. Harker LA, Mann KG. Thrombosis and fibrinolysis., In: Cardiovascular thrombosis: Thrombocardiology and thromboneurology. Verstraete M, Fuster V, Topol EJ (eds).Philadelphia, New York, Lippincott: Raven 1998; pp 3-22.
45. Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte aggregation: erythrocyte-binding site in the fibrinogen molecule. Biochimica & Biophysica Acta 1987; 904: 81-91.
46. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh artery study. Circulation 1993; 87: 1915-20.
47. Ernst E. Fibrinogen: An important risk factor for atherothrombotic diseases. Annals of Medicine 1994; 26: 15-22.
48. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996; 16: 351-6.
49. Rampling MW, Martin G. Albumin and rouleaux formation. Clinical Hemorheology 1992; 12: 761-5.
50. Putnam FW. The plasma proteins: Structure, function, and genetic control. Orlando. San Diego, New York, London, Toronto, Montreal, Sydney, Tokyo: Academic Press, Inc., 1984; pp 1-400.
51. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1988; 113: 589-97.
52. Simon E, Razavian SM, Le Beyec J, Atger V, Paul JL, Simon A, Moatti N, Levenson J. Influence of lipoprotein subtractions on dextran- and fibrinogen-induced erythrocyte aggregation. Clinical Hemorheology 1995; 15: 667-76.